Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 2, 2016, Pages 240-251

  Ashida, K ^a   Sakurai, Y ^b   Hori, T ^b   Kudou, K ^b   Nishimura, A ^b   Hiramatsu, N ^c   Umegaki, E ^d   Iwakiri, K ^e  

^a RAKUWAKAI OTOWA HOSPITAL   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; POTASSIUM COMPETITIVE ACID BLOCKER; VONOPRAZAN; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; ALLERGY; ARTICLE; BACKACHE; BRONCHITIS; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; DENTAL CARIES; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ENTEROCOLITIS; FEMALE; GASTRITIS; GASTROENTERITIS; HEALING; HUMAN; HYPERTENSION; INSOMNIA; LIVER DYSFUNCTION; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOARTHRITIS; PARALLEL DESIGN; PERIARTHRITIS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REFLUX ESOPHAGITIS; RESPIRATORY TRACT INFLAMMATION; RHINOPHARYNGITIS; STOMACH POLYP; TINEA PEDIS; TONSILLITIS; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; ESOPHAGITIS; METABOLISM; MIDDLE AGED; WOUND HEALING;

ADULT; AGED; CYTOCHROME P-450 CYP2C19; DOUBLE-BLIND METHOD; ESOPHAGITIS; FEMALE; HUMANS; LANSOPRAZOLE; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; PYRROLES; RECURRENCE; SULFONAMIDES; WOUND HEALING;

EID: 84954189862     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13461     Document Type: Article

References (20)

1. Maradey-Romero C, Fass R,. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil 2014; 20: 6-16.
2. Peery AF, Dellon ES, Lund J, et al,. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87.
3. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd,. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
4. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH,. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
5. Dent J, El-Serag HB, Wallander MA, Johansson S,. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
6. El-Serag HB, Sweet S, Winchester CC, Dent J,. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014; 63: 871-80.
7. Altomare A, Guarino MPL, Cocca S, Emerenziani S, Cicala M,. Gastroesophageal reflux disease: update on inflammation and symptom perception. World J Gastroenterol 2013; 19: 6523-8.
8. van Pinxteren B, Numans ME, Lau J, et al,. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003; 18: 755-63.
9. Fass R,. Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2012; 10: 338-45.
10. Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
11. Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
12. Matsukawa J, Hori Y, Nishida H, et al,. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol 2011; 81: 1145-51.
13. Hori Y, Matsukawa J, Takeuchi T, et al,. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011; 337: 797-804.
14. Sakurai Y, Nishimura A, Kennedy G, et al,. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6: e94. doi: 10.1038/ctg.2015.18
15. Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
16. Ashida K, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015; 42: 685-95.
17. Kahrilas PJ, Dent J, Lauritsen K, et al,. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 1385-91.
18. Farrington CP, Manning G,. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 1447-54.
19. Andersson K, Carlsson E,. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294-307.
20. Kinoshita Y, Miwa H, Kasugai K,. Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis-a phase III, multicenter, randomized, double-blind trial. Nihon Shokakibyo Gakkai Zasshi 2013; 110: 1428-38.